Dr. Shah Discusses P53-Mutated Mantle Cell Lymphoma

Video

In Partnership With:

Bijal D. Shah, MD, medical oncologist, Moffitt Cancer Center, discusses treatment for patients with p53-mutated mantle cell lymphoma (MCL).

Bijal D. Shah, MD, medical oncologist, Moffitt Cancer Center, discusses treatment for patients with p53-mutated mantle cell lymphoma (MCL).

Shah states that his first choice for patients with p53-mutated MCL is lenalidomide (Revlimid).

Additionally, Shah says that the next big biomarker will focus on minimal residual disease, as it has been shown to predict for relapse down the line.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD